Loading...
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
The treatment of patients with myelodysplastic syndromes (MDSs) has hinged primarily on supportive care (ie, blood transfusions, colony stimulating agents, iron chelation, etc.) and the US Food and Drug Administration-approved agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide. For...
Na minha lista:
| Udgivet i: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142467/ https://ncbi.nlm.nih.gov/pubmed/27913518 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|